Needham & Company Upgrades ResMed (RMD) to Buy
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $228.44 -0.67%
Rating Summary:
11 Buy, 13 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
11 Buy, 13 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Needham & Company analyst Mike Matson upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $180.00.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $153.89 yesterday.
You May Also Be Interested In
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- BNP Paribas Exane Upgrades Pony AI Inc (PONY) to Outperform
- Barclays Upgrades Crown Castle (CCI) to Overweight
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
